^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    1d
    Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study(STAR-01) (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sichuan University
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    1d
    The Transitions Project: Efficacy Trial (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Jun 2026
    Enrollment closed • Trial completion date • HEOR
    1d
    A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance (clinicaltrials.gov)
    P3, N=562, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    2d
    SGNCEA5C-001: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=165, Suspended, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Suspended
    Trial suspension
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    2d
    D907HC00001: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. (2025-521639-34-00)
    P1, N=4, Not yet recruiting, AstraZeneca AB
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • ceralasertib (AZD6738)
    3d
    Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer. (PubMed, J Thorac Oncol)
    Acquired resistance to tarlatamab plus anti-PD-1 in SCLC was associated with low DLL3 antigen expression particularly in the setting of phenotypic switch to a non-small cell lung cancer morphology and an increasingly immunosuppressive TME. Therefore, combination strategies that incorporate immune checkpoint blockade or myeloid-targeted therapies may be warranted to enhance treatment outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • DLL3 (Delta Like Canonical Notch Ligand 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • MRC1 (Mannose Receptor C-Type 1) • SYP (Synaptophysin)
    |
    DLL3 expression
    |
    Imdelltra (tarlatamab-dlle)
    4d
    The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance (clinicaltrials.gov)
    P=N/A, N=21, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Nov 2023 --> Nov 2026
    Trial completion date
    4d
    Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients. (PubMed, J Pers Med)
    A preliminary association between decreased sRAGE and overall survival in SCLC patients was observed. Serum sRAGE shows potential as a blood-based biomarker reflecting metabolic, immune, and inflammatory status in lung cancer, warranting further investigation to clarify its prognostic and therapeutic relevance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • AGER (Advanced Glycosylation End-Product Specific Receptor)
    4d
    Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC. (PubMed, Cell Biochem Funct)
    In conclusion, PrP knockdown may sensitize resistant SCLC cells to doxorubicin and promote autophagy. These findings support PrP silencing as a promising strategy to reverse chemoresistance in SCLC.
    Journal
    |
    CD44 (CD44 Molecule) • BAX (BCL2-associated X protein) • BECN1 (Beclin 1) • PRNP (Prion Protein)
    |
    doxorubicin hydrochloride
    4d
    Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (clinicaltrials.gov)
    P1, N=153, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    5d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | N=50 --> 180
    Enrollment change • Trial initiation date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    5d
    Serum ferritin change rate combined with a multidimensional inflammation model for predicting efficacy and survival in extensive-stage small-cell lung cancer patients undergoing immunotherapy: a single-center, retrospective cohort study. (PubMed, Front Immunol)
    However, NLR and LDH levels alone were not independent prognostic factors and required combined assessment with ΔSF. Our study suggests that the serum ferritin change rate combined with the NLR and LDH inflammation model can serve as a biomarker for predicting the efficacy and survival outcomes of immunotherapy in ES-SCLC.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CRP (C-reactive protein)
    |
    PD-L1 expression